Psychiatr. pro Praxi, 2007; 1: 17-21

Advances in diagnosis of Alzheimer’s disease

MUDr. Aleš Bartoš Ph.D1, RNDr. Daniela Řípová CSc2
1 Neurologická klinika 3. LF UK a FN KV, Praha
2 AD Centrum, Psychiatrické centrum Praha

New neuropsychological facts supporting long preclinical phase of Alzheimer’s disease are reviewed in the article. Simple cognitive tests provide tools to use novel information. Furthermore options and trends in neurochemical diagnosis of Alzheimer’s disease using protein triplet beta-amyloid, tau protein and phosphotau protein from cerebrospinal fluid are summarized.

Keywords: Alzheimer’s disease, diagnosis, neuropsychology, cognitive tests, biochemical markers, tau protein, beta-amyloid

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bartoš A, Řípová D. Advances in diagnosis of Alzheimer’s disease. Psychiatr. praxi. 2007;8(1):17-21.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Duff Canning SJ, Leach L, Stuss D, Ngo L, Black SE. Diagnostic utility of abbreviated fluency measures in Alzheimer disease and vascular dementia. Neurology 2004; 62: 556-562. Go to original source... Go to PubMed...
    2. Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 2003; 24: 521-536. Go to original source...
    3. Geda YE, Knopman DS, Mrazek DA, Jicha GA, Smith GE, Negash S, et al. Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch Neurol 2006; 63: 435-440. Go to original source... Go to PubMed...
    4. Hort J, Glosová L, Vyhnálek M, Bojar M, Škoda D, Hladíková M. Tau protein a beta amyloid v likvoru u Alzheimerovy choroby. Čes. a slov. Neurol. Neurochir, 2007, v tisku.
    5. Modrego PJ, Ferrandez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol 2004; 61: 1290-1293. Go to original source... Go to PubMed...
    6. Saxton J, Lopez OL, Ratcliff G, Dulberg C, Fried LP, Carlson MC, et al. Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology 2004; 63: 2341-2347. Go to original source... Go to PubMed...
    7. Starkstein SE, Mizrahi R. Depression in Alzheimer's disease. Expert Rev Neurother 2006; 6: 887-895. Go to original source... Go to PubMed...
    8. Tabert MH, Manly JJ, Liu X, Pelton GH, Rosenblum S, Jacobs M, et al. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry 2006; 63: 916-924. Go to original source... Go to PubMed...
    9. Tierney MC, Yao C, Kiss A, McDowell I. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology 2005; 64: 1853-1859. Go to original source... Go to PubMed...
    10. Vandenberghe R, Tournoy J. Cognitive aging and Alzheimer's disease. Postgrad Med J 2005; 81: 343-352. Go to original source... Go to PubMed...
    11. Wiltfang J, Lewczuk P, Riederer P, Grunblatt E, Hock C, Scheltens P, et al. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 2005; 6: 69-84. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.